People: POZEN Inc (POZN.O)

POZN.O on Nasdaq

8.75USD
10 Jul 2014
Price Change (% chg)

$-0.17 (-1.91%)
Prev Close
$8.92
Open
$8.73
Day's High
$8.85
Day's Low
$8.61
Volume
160,634
Avg. Vol
468,086
52-wk High
$9.73
52-wk Low
$4.03

Search Stocks

Summary

Name Age Since Current Position

John Plachetka

60 2001 Chairman of the Board, President, Chief Executive Officer

William Hodges

59 2004 Chief Financial Officer, Senior Vice President - Finance and Administration

Gilda Thomas

59 2007 Senior Vice President, General Counsel

Dennis McNamara

48 2014 Senior Vice President, Chief Business Officer

John Barnhardt

64 2012 Vice President - Finance and Administration

John Fort

59 2007 Chief Medical Officer

Kenneth Lee

66 2005 Lead Independent Director

Neal Fowler

52 2010 Independent Director

Arthur Kirsch

62 2004 Independent Director

Martin Nicklasson

59

Seth Rudnick

65 2011 Independent Director

Stephanie Bonestell

IR Contact Officer

Biographies

Name Description

John Plachetka

Dr. John R. Plachetka, Pharm.D. is Chairman of the Board, President, Chief Executive Officer of Pozen Inc. Prior to founding POZEN, Dr. Plachetka was Vice President of Development at Texas Biotechnology Corporation from 1993 to 1995 and was President and Chief Executive Officer of Clinical Research Foundation-America, clinical research organization, from 1990 to 1992. From 1981 to 1990, he was employed at Glaxo Inc. Dr. Plachetka received his B.S. in Pharmacy from the University of Illinois College of Pharmacy and his Doctor of Pharmacy from the University of Missouri-Kansas City.

William Hodges

Mr. William L. Hodges, CPA, is Chief Financial Officer, Senior Vice President - Finance and Administration of Pozen Inc. Mr. Hodges began his career in the pharmaceutical industry with Burroughs Wellcome Co. in 1985. In 1991, he moved to London and worked in Group Finance for the Wellcome Foundation, Ltd. Mr. Hodges worked on mergers and acquisitions and was Regional Controller for Northern Europe and Japan. In 1993, he returned to Burroughs Wellcome in North Carolina as Director of Procurement. Mr. Hodges was Vice President, Corporate Planning and Business Support at GlaxoWellcome before being appointed acting Senior Vice President and CFO for the fifteen months up to the merger between GlaxoWellcome plc and SmithKline Beecham plc which was completed in December of 2000. Prior to joining POZEN, Mr. Hodges was Senior Vice President and CFO of Pergo, Inc. located in Raleigh, North Carolina. Mr. Hodges received his B.S. from the University of North Carolina at Chapel Hill and is a Certified Public Accountant.

Gilda Thomas

Ms. Gilda M. Thomas, J.D., is Senior Vice President, General Counsel of Pozen Inc. Prior to joining POZEN, Ms. Thomas was Vice President, General Counsel and company secretary at EMD Pharmaceuticals, Inc., an affiliate of Merck KGaA, Darmstadt, Germany from July 2001 to December 2006. Prior to joining EMD, she spent 14 years at Burroughs Wellcome Co., which merged into Glaxo Welcome, Inc. At Glaxo Wellcome Ms. Thomas was Associate General Counsel responsible for the 13 member corporate section of the legal department. Ms. Thomas received her J.D. from Harvard Law School, a M.S. from Simmons College and a B.A. degree from Wellesley College.

Dennis McNamara

Mr. Dennis L. McNamara is Senior Vice President, Chief Business Officer of POZEN Inc. Mr. McNamara is responsible for leading corporate development, alliance management and intellectual property efforts at POZEN. Prior to this appointment, Mr. McNamara held the position of Vice President, Business Development at POZEN, where he has been instrumental in successfully licensing POZEN’s products and product candidates to major pharmaceutical companies, including GlaxoSmithKline, AstraZeneca AB, sanofi-aventis U.S. LLC, Horizon Pharma US, Inc., and Cilag GmbH International.

John Barnhardt

Mr. John E. Barnhardt, CPA, is Vice President - Finance and Administration of Pozen Inc. Prior to joining POZEN, Mr. Barnhardt held finance and accounting positions with publicly traded companies beginning in 1988. These positions included Chief Financial Officer of Medco Research, Inc., engaged in the research and development of pharmaceutical products primarily for the diagnosis and treatment of cardiovascular disease, and Principal Accounting Officer of Microwave Laboratories, Inc., a defense contractor developing and manufacturing traveling wave tubes for electronic countermeasure systems. Mr. Barnhardt received his B.S. in Zoology from North Carolina State University, and while employed at Ernst & Young, became a Certified Public Accountant.

John Fort

Dr. John G. Fort, M.D. MBA, is Chief Medical Officer of Pozen Inc. Prior to joining POZEN, Dr. Fort was Vice President, Medical Affairs at Adolor Corporation from 2004 until 2007. Dr. Fort held positions with Pfizer Inc., including Vice President, Medical Affairs, and was Vice President, Arthritis and Pain at G.D. Searle & Co., Monsanto Corporation from September 1994 to December 2003. Prior to joining the pharmaceutical industry, he was an Associate Professor of Medicine at Thomas Jefferson University, Division of Rheumatology. Dr. Fort received his M.D. from the University of Valencia Faculty of Medicine and is board certified in internal medicine with a subspecialty certification in rheumatology.

Kenneth Lee

Mr. Kenneth B. Lee, Jr., is Lead Independent Director of Pozen Inc. He is Independent consultant since June 2002 and general partner of Hatteras Venture Partners (formerly Hatteras BioCapital. LLC and BioVista Capital, LLC), the general partner of Hatteras BioCapital Fund, L.P., a venture capital fund focusing on life sciences companies, since 2003. President of A.M. Pappas & Associates, a venture capital firm, between January 2002 and June 2002. Partner of Ernst & Young LLP from 1982 through 2000. Partner of Ernst & Young Corporate Finance LLC from 2000 to 2001. Managing Director of Ernst & Young’s Health Sciences Corporate Finance Group from 2000 to 2001. Serves on the boards of the following public companies: Maxygen, Inc., for which he serves as chairman of the audit committee and a member of the nominating/governance committee and the compensation committee, and Biocryst Pharmaceuticals, Inc., for which he serves as chairman of the audit committee and a member of the finance committee. He is also a director of Clinverse, Inc. and Clinipace Worldwide, two privately held companies. Previously, he served on the boards of CV Therapeutics, Inc., for which he served as lead independent director and chair of the audit committee and a member of the compensation committee, Abgenix, Inc., for which he served on the audit committee, OSI Pharmaceuticals, for which he served as a member of the audit committee and Inspire Pharmaceuticals Inc., for which he served as chairman of the board of directors, chair of the audit committee and a member of the compensation committee and finance committee. Serves as a member of the executive committee of the Board of the North Carolina Biotechnology Industry Organization and as a member of the board of Ibiliti, a nonprofit organization dedicated to building and expanding networks of resources for advanced medical technology companies.

Neal Fowler

Mr. Neal F. Fowler is an Independent Director of Pozen Inc. He is Chief Executive Officer of Liquidia Technologies, Inc., a privately held biotechnology company since 2008. President of Centocor, Inc., a subsidiary of Johnson & Johnson from 2006 to 2008. President of Ortho-McNeil Neurologics, Inc., a subsidiary of Johnson & Johnson from 2004 to 2006 and Franchise Vice President-CNS from 2001 to 2004. Held various positions at Eli Lilly and Company from 1988 to 2001, including Area Director, Primary Care Division (2001), Director U.S. Cardiovascular Business Unit (1997 to 2000), Cardiovascular Product Manager (1996 to 1997), Operations Manager, Southwest Area (1995), Manager Medical Device and Diagnostics (1993 to 1995), Associate, Marketing Plans, Endocrinology (1992), Associate, Business Development/New Product Planning, Oncology (1990 to 1991), and Retail Sales Representative (1988 to 1990).

Arthur Kirsch

Mr. Arthur S. Kirsch is an Independent Director of Pozen Inc. He is Senior Advisor, GCA Savvian, LLC (formerly Perseus Group, LLC), an investment bank, since June 2005. Founding member and Managing Director of Vector Securities, LLC, an investment and merchant banking firm, from 2001 to May 2005. Managing Director and Head of Healthcare Research and Capital Markets of Prudential Vector Healthcare Group, a unit of Prudential Securities, Inc., a full-service brokerage firm, from 1999 to 2001. Director, Equity Research of Vector Securities International, Inc., an investment banking firm, from 1995 to 1999. Serves as a director of PhysioSonics, Inc., a privately held company developing noninvasive neurological products.

Martin Nicklasson

Dr. Martin Nicklasson is no longer Independent Director of Pozen Inc., effective June 4, 2014. Dr. Nicklasson is Senior Partner at Nicklasson Life Science AB, an independent consultancy and advisory company to the pharmaceutical and biotechnology sector since 2011. President and Chief Executive Officer of Biovitrum AB and Swedish Orphan Biovitrum AB, a publicly listed specialty pharma company, from 2007 to 2010. Held various executive vice president positions at AstraZeneca Plc. from 1999 to 2007, including Chairman of the Board of Astra Tech AB, a subsidiary of AstraZeneca (from 2004 to 2007), Executive Vice President, Global Marketing & Business Development (from 2005 to 2007), Executive Vice President, Global Drug Development (from 2002 to 2005) and Executive Vice President, Global Gastrointestinal Franchise (from 1999 to 2002). Serves as Chairman of the Board of Farma Holdings AS and Orexo AB and serves on the Board of Oasmia AB, Denator AB, Biocrine AB and Heart and Lung Foundation of Sweden.

Seth Rudnick

Dr. Seth A. Rudnick, M.D., is an Independent Director of Pozen Inc., since July 25, 2011. He is Venture partner and previously general partner at Canaan Partners, a venture capital firm, since 1998. Formerly, Chief Executive Officer and Chairman of CytoTherapeutics Inc., a company developing stem cell-based therapies. Helped found and served as the Head of Research and Development for Ortho Biotech, a division of Johnson & Johnson focusing on cancer and chronic illnesses from 1991 to 1998. Serves of the Boards of the following privately held biotechnology companies: Chimerix, Inc., Liquidia Technologies, Inc., ORTHOCON, Inc., Spine Wave, Inc. and VaxInnate, Inc. Currently a Clinical Adjunct Professor of Medicine at University of North Carolina, Chapel Hill.

Stephanie Bonestell

Basic Compensation

Name Fiscal Year Total

John Plachetka

2,726,560

William Hodges

626,065

Gilda Thomas

603,511

Dennis McNamara

--

John Barnhardt

623,095

John Fort

652,460

Kenneth Lee

--

Neal Fowler

--

Arthur Kirsch

--

Martin Nicklasson

--

Seth Rudnick

--

Stephanie Bonestell

--
As Of 30 Dec 2013

Options Compensation

Name Options Value

John Plachetka

1,105,094 2,464,586

William Hodges

146,645 429,367

Gilda Thomas

0 0

Dennis McNamara

0 0

John Barnhardt

226,853 1,140,353

John Fort

0 0

Kenneth Lee

0 0

Neal Fowler

0 0

Arthur Kirsch

0 0

Martin Nicklasson

0 0

Seth Rudnick

0 0

Stephanie Bonestell

0 0
Search Stocks